Adcetris (brentuximab vedotin) vs Tazverik (tazemetostat)
Adcetris (brentuximab vedotin) vs Tazverik (tazemetostat)
Adcetris (brentuximab vedotin) is an antibody-drug conjugate specifically targeting CD30, a marker on lymphoma cells, and is primarily used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Tazverik (tazemetostat) is a small molecule inhibitor of the EZH2 enzyme and is used for the treatment of epithelioid sarcoma and certain types of non-Hodgkin lymphoma. When deciding between the two, it's important to consider the specific type of cancer being treated, as Adcetris is tailored for CD30-positive lymphomas, while Tazverik targets malignancies associated with alterations in the EZH2 gene, and the decision should be guided by a healthcare professional's evaluation of the patient's individual condition and the molecular characteristics of their cancer.
Difference between Adcetris and Tazverik
| Metric | Adcetris (brentuximab vedotin) | Tazverik (tazemetostat) |
|---|---|---|
| Generic name | Brentuximab vedotin | Tazemetostat |
| Indications | Hodgkin lymphoma, systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, and certain types of mycosis fungoides | Epithelioid sarcoma, follicular lymphoma |
| Mechanism of action | Antibody-drug conjugate targeting CD30 on lymphoma cells | EZH2 inhibition, affecting gene expression in cancer cells |
| Brand names | Adcetris | Tazverik |
| Administrative route | Intravenous infusion | Oral |
| Side effects | Neutropenia, peripheral neuropathy, anemia, infusion-related reactions, fatigue, nausea | Thrombocytopenia, anemia, fatigue, nausea, musculoskeletal pain, loss of appetite |
| Contraindications | Hypersensitivity to brentuximab vedotin or any of its excipients | Hypersensitivity to tazemetostat or any of its excipients |
| Drug class | Antineoplastic agent, monoclonal antibody | Antineoplastic agent, EZH2 inhibitor |
| Manufacturer | Seattle Genetics | Epizyme, Inc. |
Efficacy
Efficacy of Adcetris (Brentuximab Vedotin) for Lymphoma
Adcetris (brentuximab vedotin) is an antibody-drug conjugate specifically indicated for the treatment of certain types of lymphoma, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). In Hodgkin lymphoma, Adcetris has shown significant efficacy, particularly in patients with relapsed or refractory disease. Clinical trials have demonstrated that Adcetris, when used after the failure of other treatments, can induce complete remission in a substantial proportion of patients. For systemic ALCL, Adcetris has been found to be effective as a single agent in patients who have relapsed or are refractory to other therapies.
The efficacy of Adcetris in Hodgkin lymphoma was highlighted in a pivotal phase III trial, which showed a marked improvement in progression-free survival (PFS) when compared with a control group receiving standard therapy. Additionally, the overall response rate (ORR) and complete remission rates were significantly higher in the Adcetris-treated group. These outcomes have established Adcetris as a key therapeutic option for patients with relapsed or refractory Hodgkin lymphoma.
Efficacy of Tazverik (Tazemetostat) for Lymphoma
Tazverik (tazemetostat) is an oral, selective inhibitor of the EZH2 enzyme and has been approved for the treatment of epithelioid sarcoma. However, its use in lymphoma, specifically follicular lymphoma, has shown promise in clinical trials. Tazverik has demonstrated efficacy in patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. The drug has been granted accelerated approval by the FDA for this indication based on overall response rate, with continued approval contingent upon verification of clinical benefit in confirmatory trials.
In clinical studies, Tazverik has shown an ability to induce partial or complete responses in a subset of patients with follicular lymphoma. The ORR and duration of response (DOR) have been encouraging, with some patients achieving a sustained response to the treatment. These results suggest that Tazverik may offer a new therapeutic mechanism for patients with this type of lymphoma, particularly for those who have exhausted other treatment options.
Regulatory Agency Approvals
Adcetris
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
-
NMPA (China)
Tazverik
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Adcetris or Tazverik today
If Adcetris or Tazverik are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us